<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431351</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-014</org_study_id>
    <nct_id>NCT02431351</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients</brief_title>
  <acronym>SIER</acronym>
  <official_title>A Phase 2, Open-Label, Single Arm Study Evaluating the Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Erythropoietin (EPO)-Refractory Lower-Risk Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study designed to evaluate the safety and efficacy of the selective&#xD;
      inhibitor of nuclear export (SINE) compound, Selinexor given orally to patients with&#xD;
      transfusion-dependent, EPO-refractory lower-risk MDS (Low risk and Intermediate-1 as defined&#xD;
      by IPSS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, open-label, study designed to evaluate the safety and efficacy of the&#xD;
      selective inhibitor of nuclear export (SINE) compound, Selinexor given orally to patients&#xD;
      with transfusion-dependent, EPO-refractory lower-risk MDS (Low risk and Intermediate-1 as&#xD;
      defined by IPSS). Patients will be dosed at the clinic on clinic visit days and received&#xD;
      Selinexor for dosing at home on additional days.&#xD;
&#xD;
      Patients will be evaluated for disease response according to the 2006 IWG response criteria&#xD;
      for MDS. This includes evaluation for altering the natural history of disease, cytogenic&#xD;
      response hematologic improvement, and quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Trial never opened.&#xD;
  </why_stopped>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematologic improvement (based on the 2006 International Working Group (IWG) response criteria)</measure>
    <time_frame>6 months</time_frame>
    <description>Hematologic improvement in erythroid, platelet, and neutrophil counts, evaluated based on the 2006 International Working Group (IWG) response criteria for MDS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Overall response is defined as complete remission (CR) or partial remission (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL-E) MDS Questionnaire)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate quality of life using the Quality of Life-E (QOL-E) MDS Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Selinexor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.</description>
    <arm_group_label>Selinexor</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Low risk or Intermediate-1 risk MDS with any cytogenetic abnormalities&#xD;
             (according to the IPSS criteria); patients must have bone marrow biopsy/aspiration or&#xD;
             tumor tissue available from within 1 month prior to first dose or collected during the&#xD;
             Screening period.&#xD;
&#xD;
          -  Patients &gt;18 years at Screening who are not candidates for hematopoietic cell&#xD;
             transplantation.&#xD;
&#xD;
          -  Received 1 prior line of treatment; typically erythroid-stimulating agents (ESAs).&#xD;
&#xD;
          -  Red blood cell (RBC) transfusion-dependent anemia while treated with or after&#xD;
             discontinuation of EPO. Transfusion dependence is defined as the requirement for at&#xD;
             least 2 units of RBCs transfused during the 8 weeks prior to study initiation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of recombinant EPO within 8 weeks prior to screening.&#xD;
&#xD;
          -  Patient has a concurrent active malignancy or prior history of malignancy other than&#xD;
             MDS (except basal cell or squamous cell carcinoma of the skin and in situ of the&#xD;
             cervix) unless free of disease for at least 1 year.&#xD;
&#xD;
          -  Unstable cardiovascular function:&#xD;
&#xD;
               -  Symptomatic ischemia,&#xD;
&#xD;
               -  Uncontrolled clinically significant conduction abnormalities (i.e., ventricular&#xD;
                  tachycardia on anti-arrhythmic agents are excluded; 1st degree atrioventricular&#xD;
                  (AV) block or asymptomatic Left anterior fascicular block/Right bundle branch&#xD;
                  block (LAFB/RBBB) will not be excluded), or&#xD;
&#xD;
               -  Congestive heart failure (CHF) New York Heart Association (NYHA) Class ≥3, or&#xD;
                  myocardial infarction (MI) within 3 months.&#xD;
&#xD;
          -  Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals&#xD;
             within 1 week prior to first dose. Infections controlled on concurrent anti-microbial&#xD;
             agents are acceptable, and anti-microbial prophylaxis per institutional guidelines is&#xD;
             acceptable.&#xD;
&#xD;
          -  Active bleeding Grade 3-4, in the last 4 weeks prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2015</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KPT-330</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>Selinexor</keyword>
  <keyword>SIER</keyword>
  <keyword>Myelodysplastic Syndrome (MDS)</keyword>
  <keyword>Erythropoietin (EPO)</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

